[1]苏毅,赖思含,易海,等.异基因造血干细胞移植术治疗自体造血干细胞移植术后复发的恶性淋巴瘤17例效果分析[J].第三军医大学学报,2012,34(24):2456-2458.
 Su Yi,Lai Sihan,Yi Hai,et al.Allogeneic hematopoietic stem cell transplantation for recurrent lymphoma after autologous stem cell transplantation: clinical analysis of 17 cases[J].J Third Mil Med Univ,2012,34(24):2456-2458.
点击复制

异基因造血干细胞移植术治疗自体造血干细胞移植术后复发的恶性淋巴瘤17例效果分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
34卷
期数:
2012年第24期
页码:
2456-2458
栏目:
论著
出版日期:
2012-12-30

文章信息/Info

Title:
Allogeneic hematopoietic stem cell transplantation for recurrent lymphoma after autologous stem cell transplantation: clinical analysis of 17 cases
作者:
苏毅赖思含易海付利范方毅孙浩平刘阳阳邓涛王译何光翠
成都军区总医院血液科
Author(s):
Su Yi Lai Sihan Yi Hai Fu Li Fan Fangyi Sun Haoping Liu Yangyang Deng Tao Wang Yi He Guangcui
Department of Hematology, General Hospital of Chengdu Military Command, Chengdu, Sichuan Province, 610083, China
关键词:
异基因造血干细胞移植自体造血干细胞移植复发淋巴瘤
Keywords:
allogeneic hematopoietic stem cell transplantation autologous hematopoietic stem cell transplantation recurrence lymphoma
分类号:
R617;R730.6;R733.4
文献标志码:
A
摘要:
目的      观察异基因造血干细胞移植治疗自体造血干细胞移植后复发的恶性淋巴瘤的临床效果。      方法      本科2000-2011年采用异基因亲缘造血干细胞移植术治疗自体造血干细胞移植术后复发的恶性淋巴瘤患者17例,HLA配型全相合(6/6相合)10例,5/6相合5例,4/6相合2例。预处理方案采用环磷酰胺120 mg/kg分2 d静滴,马利兰12~14 mg/kg分4 d口服,氟达拉滨30 mg/m2×5 d。全相合供体采用CsA+MTX+MMF预防移植物抗宿主病(graft-versus-host disease, GVHD),不全相合供体采用ATG+CsA+MTX+MMF预防GVHD。移植物均为外周血造血干细胞加骨髓。      结果      17例患者均获造血重建,发生急性GVHD 9例(52.94%),发生慢性GVHD 11例(64.71%)。随访12~120个月,6例患者分别于移植后8、11、15、19、21、34个月疾病复发而死亡,3例患者死于GVHD合并感染,余8例健康存活。      结论      异基因造血干细胞移植是治疗自体造血干细胞移植后复发的恶性淋巴瘤患者的有效方法。
Abstract:
Objective      To observe the clinical efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on recurrent lymphoma after autologous stem cell transplantation (auto-HSCT).        Methods      A total of 17 patients with recurrent lymphoma after auto-HSCT underwent allo-HSCT in our department from January 2000 to December 2011. There were human leukocyte antigen (HLA) full matched (6/6) in 10 patients, 5/6 matched in 5, and 4/6 matched in 2. All patents were treated with standardized conditioning regimen consisting of cyclophosphamide 120 mg/kg in 2 d, busulfan 12 to 14 mg/kg in 4 d by oral taking, and fludarabine 30 mg/m2 for 1 to 5 d. Graft-versus-host disease (GVHD) was prevented by CsA+MTX+MMF for HLA full-matched and ATG +CsA +MTX+MMF for mismatched. Grafts were peripheral blood stem cells and bone marrow.       Results      Hematopoietic reconstitution achieved in all 17 patients. There were 9 cases (52.94%) with acute GVHD, and 11 cases (64.70%) with chronic GVHD. During the follow-up period of 12 to 120 month, 6 patients died of disease recurrence after transplantation 8, 11, 15, 19, 21, and 34 months respectively, 3 died of GVHD with infection, and 8 survived until now.       Conclusion      Allo-HSCT is an effective therapy for recurrent lymphoma after auto-HSCT.

参考文献/References:

苏毅, 赖思含, 易海, 等. 异基因造血干细胞移植术治疗自体造血干细胞移植术后复发的恶性淋巴瘤17例效果分析[J]. 第三军医大学学报,2012,34(24):2456-2458.

相似文献/References:

[1]陈姝,李文,罗云,等.减低剂量Bu+Cy预处理方案进行异基因造血干细胞移植治疗白血病的效果观察[J].第三军医大学学报,2012,34(24):2442.
 Chen Shu,Li Wen,Luo Yun,et al.Therapeutic effect of allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen of Bu+Cy for leukemia[J].J Third Mil Med Univ,2012,34(24):2442.
[2]刘嘉,高蕾,张曦,等.异基因造血干细胞移植联合伊马替尼治疗成人Ph+急性淋巴细胞白血病临床观察[J].第三军医大学学报,2012,34(24):2453.
 Liu Jia,Gao Lei,Zhang Xi,et al.Clinical efficiency of allogenic hematopoietic stem cell transplantation combined with imatinib in treatment of Philadelphia positive acute lymphoblastic leukemia[J].J Third Mil Med Univ,2012,34(24):2453.
[3]孙志强,王季石,卢英豪,等.自体造血干细胞移植治疗鼻腔NK/T细胞淋巴瘤并皮肤浸润1例[J].第三军医大学学报,2010,32(06):536.
[4]梁雪,陈幸华,孔佩艳,等.异基因造血干细胞移植后肠道移植物抗宿主病临床分析[J].第三军医大学学报,2009,31(21):2158.
[5]颜红菊,唐伦,高蕾,等.单倍体与同胞全相合造血干细胞移植治疗高危急性淋巴细胞白血病疗效观察[J].第三军医大学学报,2016,38(12):1340.
 Yan Hongju,Tang Lun,Gao Lei,et al.Efficacy of haploid-matched vs sibling-matched allogeneic stem cell transplantation for high risk acute lymphoblastic leukemia[J].J Third Mil Med Univ,2016,38(24):1340.
[6]王晓果,陈婷,刘焕凤,等.小剂量地西他滨在异基因造血干细胞移植后早期复发及cGVHD治疗中的作用[J].第三军医大学学报,2016,38(12):1362.
 Wang Xiaoguo,Chen Ting,Liu Huanfeng,et al.Role of small-dose decitabine in treatment of early recurrence and chronic graft versus host disease after allogeneic hematopoietic stem cell transplantation[J].J Third Mil Med Univ,2016,38(24):1362.
[7]刘红云,陈果,曾韫璟,等.脐带间充质细胞对异基因造血干细胞移植术后出血性膀胱炎的疗效及安全性分析[J].第三军医大学学报,2019,41(23):2296.
 LIU Hongyun,CHEN Guo,ZENG Yunjing,et al.Efficiency and safety of umbilical cord mesenchymal stromal cell infusion in treatment of hemorrhagic cystitis after allogenic hematopoietic stem cell transplantation[J].J Third Mil Med Univ,2019,41(24):2296.
[8]蔺诗佳,刘雨青,姚浛,等.EVI1基因阳性的急性髓系白血病患者临床特点及其造血干细胞移植的疗效观察[J].第三军医大学学报,2020,42(17):1699.
 LIN Shijia,LIU Yuqing,YAO Han,et al.Clinical characteristics of EVI1+ AML and clinical observation of hematopoietic stem cell transplantation on these patients[J].J Third Mil Med Univ,2020,42(24):1699.
[9]陆铉,严晗,夏凌辉.缬更昔洛韦抢先治疗异基因造血干细胞移植后巨细胞病毒血症的临床研究[J].第三军医大学学报,2020,42(17):1706.
 LU Xuan,YAN Han,XIA Ling.Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation[J].J Third Mil Med Univ,2020,42(24):1706.

更新日期/Last Update: 2012-12-19